How many insider trades does FilingIQ track for HURA?

FilingIQ tracks 10 Form 4 insider transactions for HURA (TuHURA Biosciences, Inc./NV), covering filings from Dec 12, 2025 onwards. 1 of those were filed in the last 90 days.

Are HURA insiders net buyers or net sellers?

Across the full Form 4 history for HURA, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does HURA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is HURA in?

TuHURA Biosciences, Inc./NV (HURA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $63.82M.

HURA insider trading

Healthcare

TuHURA Biosciences, Inc./NV — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 0%

Market cap

$63.82M

About TuHURA Biosciences, Inc./NV

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.

Company website: www.tuhurabio.com

HURA insider activity at a glance

FilingIQ has scored 10 insider transactions for HURA since Dec 12, 2025. The most recent filing in our index is dated May 28, 2026.

Across the full history, 0 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live HURA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,165

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 191

Guardant Health, Inc.

KYMR 178

Kymera Therapeutics, Inc.

First Tracks Biotherapeutics, Inc.

Top insiders trading HURA

Ng George K

12 trades · score 71.8

Politicians who have traded HURA

Lee, Laurel

U.S. Rep. , FL · 11 trades

Frequently asked

How many insider trades does FilingIQ track for HURA?: FilingIQ tracks 10 Form 4 insider transactions for HURA (TuHURA Biosciences, Inc./NV), covering filings from Dec 12, 2025 onwards. 1 of those were filed in the last 90 days.
Are HURA insiders net buyers or net sellers?: Across the full Form 4 history for HURA, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does HURA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is HURA in?: TuHURA Biosciences, Inc./NV (HURA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $63.82M.

Methodology & sources

Every HURA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.